EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Serotonin–Norepinephrine Reuptake Inhibitors in Fibromyalgia Management: An Integrative Literature Review of Clinical Evidence

Isabella Oliveira do Lago, Bruna Moura Medina Diniz, Daniela Vieira Buchaim iD, Rogerio Leone Buchaim iD

Clinics and Practice · 28.03.2026 · 16 (4) · 68

DOI: 10.3390/clinpract16040068 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinics and Practice, online erschienen am 28.03.2026. Verfasst von Isabella Oliveira do Lago und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bauru School of Medicine, University of Sao Paulo (FMBRU/USP), Bauru 17012-901, Brazil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, National Council for Scientific and Technological Development https://ror.org/03swz6y49.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibromyalgia (FM) is a chronic pain syndrome characterized by central sensitization and impaired pain modulation, involving dysfunctional descending inhibitory pathways and altered nociceptive processing. These processes contribute to persistent musculoskeletal pain, difficulties with sleep, feelings of depression, and ongoing fatigue. Serotonin and norepinephrine are key mediators of pain control, and evidence indicates that dual reuptake inhibition provides superior analgesia compared to single-pathway approaches. Accordingly, serotonin–norepinephrine reuptake inhibitors (SNRIs), including milnacipran and duloxetine, approved for FM treatment, show favorable efficacy and tolerability compared with tricyclic antidepressants. This integrative literature review aimed to evaluate the impact of SNRIs on musculoskeletal pain, fatigue, depression, and quality of life in patients with FM by analyzing randomized clinical trials (RCTs), identified via PubMed/MEDLINE searches (2015–2025) in English/Portuguese using descriptors: “Fibromyalgia”, “Serotonin and Norepinephrine Reuptake Inhibitors”, “Duloxetine” and “Milnacipran”. From 195 records screened, 18 studies met inclusion criteria (9.2% inclusion rate); duloxetine evaluated in 16 studies (88.9%), milnacipran in 2 (11.1%); SNRIs demonstrated superior efficacy vs. placebo: pain reduction 30–40%, fatigue improvement 25%, quality of life enhancement 20%. SNRIs were overall more effective than placebo but did not achieve high levels of analgesia, underscoring the need for further research on long-term efficacy and comparisons with combination pharmacological and non-pharmacological therapies. SNRIs significantly alleviate musculoskeletal pain (30–50% of patients), fatigue, depression symptoms, and improve quality of life in FM versus placebo. Duloxetine showed superior efficacy for pain/depression; milnacipran excelled in sleep quality. Long-term studies and combination therapies warrant further investigation.

Schlagwörter

Stichwörter der Autor:innen

central sensitizationchronic widespread paindesvenlafaxinerandomized clinical trialsvenlafaxine

Autor:innen und Institutionen

  • Bauru School of Medicine, University of Sao Paulo (FMBRU/USP), Bauru 17012-901, Brazil.
  • Ribeirão Preto School of Medicine, University of Sao Paulo (FMRP/USP), Ribeirão Preto 14049-900, Brazil.
  • Medical School, University Center of Adamantina (FAI), Adamantina 17800-000, Brazil.
  • Center for the Study of Venoms and Venomous Animals (CEVAP), Sao Paulo State University (UNESP), Botucatu 18610-307, Brazil.
  • Postgraduate Department, Dentistry School, Faculty of the Midwest Paulista (FACOP), Piratininga 17499-010, Brazil.
  • Graduate Program in Anatomy of Domestic and Wild Animals, Faculty of Veterinary Medicine and Animal Science, University of Sao Paulo (FMVZ/USP), Sao Paulo 05508-270, Brazil.

ORCID-Profile: Daniela Vieira Buchaim, Rogerio Leone Buchaim

Förderung

  • National Council for Scientific and Technological Development
  • National Council for Scientific and Technological Development https://ror.org/03swz6y49

Zitieren

APA

Lago, I. O. D., Diniz, B. M. M., Buchaim, D. V., & Buchaim, R. L. (2026). Serotonin–Norepinephrine Reuptake Inhibitors in Fibromyalgia Management: An Integrative Literature Review of Clinical Evidence. Clinics and Practice, 16(4), 68. https://doi.org/10.3390/clinpract16040068

Vancouver

Lago IOD, Diniz BMM, Buchaim DV, Buchaim RL. Serotonin–Norepinephrine Reuptake Inhibitors in Fibromyalgia Management: An Integrative Literature Review of Clinical Evidence. Clinics and Practice. 2026;16(4):68. doi:10.3390/clinpract16040068

BibTeX
@article{Lago2026,
  author = {Lago, Isabella Oliveira do and Diniz, Bruna Moura Medina and Buchaim, Daniela Vieira and Buchaim, Rogerio Leone},
  title = {Serotonin–Norepinephrine Reuptake Inhibitors in Fibromyalgia Management: An Integrative Literature Review of Clinical Evidence},
  journal = {Clinics and Practice},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {68},
  doi = {10.3390/clinpract16040068}
}
Kostenlos starten →